Greenwich Lifesciences Stock Current Liabilities
| GLSI Stock | USD 12.00 0.22 1.87% |
Greenwich Lifesciences fundamentals help investors to digest information that contributes to Greenwich Lifesciences' financial success or failures. It also enables traders to predict the movement of Greenwich Stock. The fundamental analysis module provides a way to measure Greenwich Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Greenwich Lifesciences stock.
The current Total Current Liabilities is estimated to decrease to about 251.7 K. Non Current Liabilities Total is expected to grow at the current pace this year. Greenwich | Current Liabilities |
Greenwich Lifesciences Company Current Liabilities Analysis
Greenwich Lifesciences' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Greenwich Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Greenwich Lifesciences is extremely important. It helps to project a fair market value of Greenwich Stock properly, considering its historical fundamentals such as Current Liabilities. Since Greenwich Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Greenwich Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Greenwich Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Greenwich Current Liabilities Historical Pattern
Today, most investors in Greenwich Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Greenwich Lifesciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Greenwich Lifesciences current liabilities as a starting point in their analysis.
Greenwich Lifesciences Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Greenwich Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Greenwich Lifesciences has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Greenwich Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Greenwich Lifesciences' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Greenwich Lifesciences could also be used in its relative valuation, which is a method of valuing Greenwich Lifesciences by comparing valuation metrics of similar companies.Greenwich Lifesciences is currently under evaluation in current liabilities category among its peers.
Greenwich Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Greenwich Lifesciences from analyzing Greenwich Lifesciences' financial statements. These drivers represent accounts that assess Greenwich Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Greenwich Lifesciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 434.6M | 287.7M | 182.8M | 128.2M | 147.4M | 240.3M |
Greenwich Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Greenwich Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Greenwich Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
Greenwich Fundamentals
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.9 | ||||
| Current Valuation | 149.02 M | ||||
| Shares Outstanding | 13.14 M | ||||
| Shares Owned By Insiders | 53.05 % | ||||
| Shares Owned By Institutions | 8.44 % | ||||
| Number Of Shares Shorted | 653.14 K | ||||
| Price To Book | 31.08 X | ||||
| EBITDA | (9.32 M) | ||||
| Net Income | (8.89 M) | ||||
| Cash And Equivalents | 15.64 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 294.41 K | ||||
| Current Ratio | 65.74 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (6.48 M) | ||||
| Short Ratio | 31.07 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 38.0 | ||||
| Beta | 3.32 | ||||
| Market Capitalization | 154.84 M | ||||
| Total Asset | 6.99 M | ||||
| Retained Earnings | (50.36 M) | ||||
| Working Capital | 6.7 M | ||||
| Net Asset | 6.99 M |
About Greenwich Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Greenwich Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Greenwich Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Greenwich Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:Check out Greenwich Lifesciences Piotroski F Score and Greenwich Lifesciences Altman Z Score analysis. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.